Here are the DEF 14A proxy statements from Bowen Acquisition Corp (BOWN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BOWN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOWN filings page.
Bowen Acquisition Corp is asking shareholders to approve an extension of its SPAC deadline to complete a business combination from June 14, 2026 to as late as December 31, 2026, and to approve a possible adjournment of the meeting if more time is needed.
The SPAC has a pending, already‑approved merger with Shenzhen Qianzhi BioTechnology but has not yet closed it. Public shareholders can elect to redeem their shares for cash from the trust account, estimated at about $11.55 per share based on approximately $7.78 million held in trust as of May 22, 2026, if they submit redemption requests by June 9, 2026.
If the extension is not approved and no deal is completed by June 14, 2026, Bowen would wind up, redeem all public shares from the trust and liquidate, while founder and private shares would receive no trust proceeds. Sponsors and insiders hold about 70.3% of outstanding shares and intend to vote in favor of the extension, effectively assuring its approval if all shares vote. The proxy also highlights risks including prior Nasdaq delisting, limited trading liquidity, potential Investment Company Act issues, CFIUS-related constraints because of foreign ties, and conflicts of interest for sponsors and management.
Bowen Acquisition Corp (BOWN) is calling an extraordinary general meeting on December 12, 2025 for shareholders to vote on extending the deadline to complete its initial business combination. The Extension Proposal would allow the board to push the current termination date from December 14, 2025 by up to six one‑month increments, to as late as June 14, 2026. A separate Adjournment Proposal would let the board adjourn the meeting if more time is needed to secure approval.
Bowen has a signed deal with Shenzhen Qianzhi BioTechnology Co. Ltd., which shareholders approved in January 2025 but has not yet closed. Public shareholders may elect to redeem their shares for cash; based on about $8.26 million in the trust as of November 20, 2025, the company estimates a redemption price of roughly $11.35 per share. If the Extension Proposal fails and no deal closes by December 14, 2025, Bowen would redeem all public shares and liquidate. Shareholders who do not redeem now, and did not redeem at the earlier Qianzhi vote, will not have redemption rights when that business combination is completed.